Impact on BioMarin’s Sentiment: Voxzogo’s Triumph Clouded by Uncertainty
Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in
Benzinga’s Top Ratings Upgrades, Downgrades For September 28, 2023
Upgrades According to Northcoast Research, the prior rating for Essential Utilities Inc (NYSE:WTRG) was changed from Neutral to…
BioMarin To Present Data Showing Long-Term Benefit Of VOXZOGO On Growth In Children With Achondroplasia At 2023 European Society For Paediatric Endocrinology Meeting
Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4SAN RAFAEL, Calif., Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a global biotechnology company
Benzinga’s Top Ratings Upgrades, Downgrades For September 18, 2023
Upgrades Northcoast Research upgraded the previous rating for Jack Henry & Associates Inc (NASDAQ:JKHY) from Neutral to Buy.…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
BioMarin Announces First Person Treated Commercially With ROCTAVIAN For Severe Hemophilia A In Europe
First Person Treated in Germany; Reimbursement Discussions on Track in France and Italy
In the U.S., ROCTAVIAN Now Commercially Available and Hemophilia Treatment Centers Have Begun Screening
Biomarin’s Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q2 adjusted EPS of $0.54, higher than $0.41 a year ago and beating the
Earnings Scheduled For July 31, 2023
Companies Reporting Before The Bell
• Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.
Earnings Outlook For Biomarin Pharmaceutical
Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Monday, 2023-07-31. Here’s what investors…